ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 703

Isotretinoin-Induced Spondilartropathy-Related Symptoms: A Prospective Study

Bunyamin Kisacik1, Nuriye Kayiran2, Orhan Zengin1, Ali Kalem3, Gezmis Kimyon4, Emine Ozkul Kilinc3, Yavuz Pehlivan5, Necmettin Kirtak6 and Ahmet Mesut Onat4, 1İnternal Medicine Division of Rheumatology, Gaziantep University, Faculty of Medicine, Gaziantep, Turkey, 2physician, Gaziantep, Turkey, 3Physician, Gaziantep, Turkey, 4PsART study group, Ankara, Turkey, 5Department of Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, 6Prof., Gaziantep, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Drug interactions and spondylarthropathy

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Acne vulgaris is a chronic inflammatory disease of accumulation of the pilosebaceous unit in the skin and has a multifactorial aetiology. Isotretinoin is a one of the systemic retinoids and is an effective treatment option for severe and treatment-resistant acne. However, isotretinoin can cause rheumatologic. We aimed to present follow-up results in terms of rheumatologic symptoms of the patients who received systemic therapy for the treatment of acne (isotretinoin and tetracycline) in this prospective, observational study.

Methods: Forty-five patients were started on isotretinoin and 32 patients were started on tetracycline for acne treatment in 2011. Patients were evaluated by rheumatologic symptoms, rheumatological examination, erythrocyte sedimentation rate, C-reactive protein and the Bath Ankylosing Spondylitis Disease Activity (BASDAI) scoring before the treatment, at the time of acute symptoms and after the treatment on 3rd and 6thmonths.

Results: Unilateral Achilles enthesopathy had developed in 3 patients, both Achilles enthesopathy and unilateral sacroiliitis had developed in 1 patient, and inflammatory low back pain had developed in 6 patients in the isotretinoin group; on the other hand, no rheumatologic symptoms were observed in the tetracycline group.

Conclusion: As a result, spondialartropathy (SPA) findings were determined in up to 23.1% of the patients who received isotretinoin treatment.


Disclosure: B. Kisacik, None; N. Kayiran, None; O. Zengin, None; A. Kalem, None; G. Kimyon, None; E. Ozkul Kilinc, None; Y. Pehlivan, None; N. Kirtak, None; A. M. Onat, None.

To cite this abstract in AMA style:

Kisacik B, Kayiran N, Zengin O, Kalem A, Kimyon G, Ozkul Kilinc E, Pehlivan Y, Kirtak N, Onat AM. Isotretinoin-Induced Spondilartropathy-Related Symptoms: A Prospective Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/isotretinoin-induced-spondilartropathy-related-symptoms-a-prospective-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/isotretinoin-induced-spondilartropathy-related-symptoms-a-prospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology